Top

Published in:

01-07-2006 | Original Article

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

Authors: Terzah M. Horton, Anurhadha Gannavarapu, Susan M. Blaney, David Z. D’Argenio, Sharon E. Plon, Stacey L. Berg

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2006

Abstract

Although there is effective chemotherapy for many patients with leukemia, 20% of children and up to 65% of adults relapse. Novel therapies are needed to treat these patients. Leukemia cells are very sensitive to the proteasome inhibitor bortezomib (VELCADE®, PS-341), which enhances the in vitro cytotoxic effects of dexamethasone and doxorubicin in multiple myeloma. To determine if bortezomib enhances the cytotoxicity of agents used in leukemia, we employed an in vitro tetrazolium-based colorimetric assay (MTT) to evaluate the cytotoxic effects of bortezomib alone and in combination with dexamethasone, vincristine, doxorubicin, cytarabine, asparaginase, geldanamycin, trichostatin A, and the bcl-2 inhibitor HA14.1. We demonstrated that primary leukemia lymphoblasts and leukemia cell lines are sensitive to bortezomib, with an average IC₅₀ of 12 nM. Qualitative and quantitative bortezomib-drug interactions were evaluated using the universal response surface approach (URSA). Bortezomib was synergistic with dexamethasone in dexamethasone-sensitive leukemia cells, and additive with vincristine, asparaginase, cytarabine, and doxorubicin. The anti-leukemic activity of bortezomib was also additive with geldanamycin and HA14.1, and additive or synergistic with trichostatin A. These results were compared to analysis using the median-dose effect method, which generated complex drug interactions due to differences in dose-response curve sigmoidicities. These data suggest bortezomib could potentiate the cytotoxic effects of combination chemotherapy in patients with leukemia.

SEER Cancer Statistic Review, 1973–1999 Bethesda, MD: National Cancer Institute, 2000;467–482

Hochstrasser M (1995) Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 7:215–223PubMedCrossRef

Spataro V, Norbury C, Harris AL (1998) The ubiquitin-proteasome pathway in cancer. Br J Cancer 77:448–455PubMed

Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79:13–21PubMedCrossRef

Karin M, Cao Y, Greten FR et al (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301–310PubMedCrossRef

Hideshima T, Chauhan D, Richardson P et al (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639–16647PubMedCrossRef

Shinohara K, Tomioka M, Nakano H et al (1996) Apoptosis induction resulting from proteasome inhibition. Biochem J 317(Pt 2):385–388PubMed

Drexler HC (1997) Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad.Sci USA 94:855–860PubMedCrossRef

Adams J, Palombella VJ, Sausville EA et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615–2622PubMed

10.

Papandreou CN, Daliani DD, Nix D et al (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108–2121PubMedCrossRef

11.

Orlowski RZ, Stinchcombe TE, Mitchell BS et al (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420–4427PubMedCrossRef

12.

Masdehors P, Merle-Beral H, Magdelenat H et al (2000) Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk Lymphoma 38:499–504PubMed

13.

Hideshima T, Richardson P, Chauhan D et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071–3076PubMed

14.

Soligo D, Servida F, Delia D et al (2001) The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 113:126–135PubMedCrossRef

15.

Mitsiades N, Mitsiades CS, Richardson PG et al (2002) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377–2380PubMedCrossRef

16.

Pajonk F, Pajonk K, McBride WH (2000) Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 47:1025–1032PubMed

17.

Dai Y, Rahmani M, Grant S (2003) Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 22:7108–7122PubMedCrossRef

18.

Dai Y, Rahmani M, Pei XY et al (2004) Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 104:509–518PubMedCrossRef

19.

Mitsiades CS, Mitsiades NS, McMullan CJ et al (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101:540–545PubMedCrossRef

20.

Adachi M, Zhang Y, Zhao X et al (2004) Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin Cancer Res 10:3853–3862PubMedCrossRef

21.

Pei XY, Dai Y, Grant S (2003) The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 17:2036–2045PubMedCrossRef

22.

Wang CY, Mayo MW, Korneluk RG et al (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680–1683PubMedCrossRef

23.

Wang CY, Cusack JC Jr, Liu R et al (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nature Medicine 5:412–417PubMedCrossRef

24.

Izban KF, Ergin M, Huang Q et al (2001) Characterization of NF-kappaB expression in Hodgkin’s disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod.Pathol 14:297–310PubMedCrossRef

25.

Richardson PG, Hideshima T, Mitsiades C et al (2004) Proteasome inhibition in hematologic malignancies. Ann Med 36:304–314PubMedCrossRef

26.

Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487–2498PubMedCrossRef

27.

O’Connor OA, Wright J, Moskowitz C et al (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol 23:676–684PubMedCrossRef

28.

Goy A, Younes A, McLaughlin P et al (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol 23:667–675PubMedCrossRef

29.

An WG, Hwang SG, Trepel JB et al (2000) Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14:1276–1283PubMedCrossRef

30.

Yu C, Rahmani M, Dent P et al (2004) The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res 295:555–566PubMedCrossRef

31.

Tan C, Waldmann TA (2002) Proteasome inhibitor PS-341, a potential therapeutic agent for adult T- cell leukemia. Cancer Res 62:1083–1086PubMed

32.

Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63PubMedCrossRef

33.

Carmichael J, DeGraff WG, Gazdar AF et al (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936–942PubMed

34.

Greco WR, Park HS, Rustum YM (1990) Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res 50:5318–5327PubMed

35.

DiArgenio DZ, Schumitsky A (1997)ADAPT II Users guide: pharmacokinetic/pharmacodynamic systems analysis software. (4). Los Angeles, CA, Biomedical systems resource

36.

Chou T, Talalay C (1984) Quantitative analysis of dose effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55PubMedCrossRef

37.

Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617PubMedCrossRef

38.

Appleman LJ, Ryan DP, Clark JW, Eder JP, Fishman M, Cusack JC Jr, Fidias P, Supko JG, Guerciolini R, Esseltine D, Kashala O (2003) Phase I dose escalation study of bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors. Proc ASCO 22:A839

39.

Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29(Suppl 1):21–31PubMedCrossRef

40.

Gatto S, Scappini B, Pham L et al (2003) The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in B positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88:853–863PubMed

41.

Yu C, Rahmani M, Conrad D et al (2003) The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102:3765–3774PubMedCrossRef

42.

An J, Sun Y, Fisher M et al (2004) Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 18:1699–1704PubMedCrossRef

43.

Zheng B, Georgakis GV, Li Y et al (2004) Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 10:3207–3215PubMedCrossRef

44.

Chauhan D, Li G, Auclair D et al (2004) 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. Apoptosis 9:149–155PubMedCrossRef

45.

Brown RE, Bostrom B, Zhang PL (2004) Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia. Ann.Clin Lab Sci 34:203–205PubMed

46.

Webb JL (1963) effect of more than one inhibitor. Enzymes and metabolic inhibitors ed Vol 1; New York: Academic Press, 66-79-487-512

47.

Faessel HM, Slocum HK, Jackson RC et al (1998) Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation. Cancer Res 58:3036–3050PubMed

48.

Chou JH (1991) Quantitation of synergism and antagonism of two or more drugs by computerized analysis. Synergism and antagonism in chemotherapy pp 223–241

49.

Pei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezmib and histone deacetylase inhibitors. Clin Cancer Res 10:3839–3852PubMedCrossRef

50.

Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47:331–385PubMed

51.

Berenbaum MC (1989) What is synergy? Pharmacol Rev 41:93–141PubMed

52.

Zoli W, Ricotti L, Tesei A et al (2001) In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 37:69–82PubMedCrossRef

53.

Chang TT, Chou TC (2000) Rational approach to the clinical protocol design for drug combinations: a review. Acta Paediatr Taiwan 41:294–302PubMed

54.

Bonvini P, Dalla RH, Vignes N et al (2004) Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res 64:3256–3264PubMedCrossRef

55.

Richardson PG, Hideshima T, Mitsiades C et al (2004) Proteasome inhibition in hematologic malignancies. Ann Med 36:304–314PubMedCrossRef

56.

Blaney SM, Bernstein M, Neville K et al (2004) Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children’s Oncology Group study (ADVL0015). J Clin Oncol 22:4752–4757CrossRef

57.

Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55PubMedCrossRef

Title: Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
Authors: Terzah M. Horton
Anurhadha Gannavarapu
Susan M. Blaney
David Z. D’Argenio
Sharon E. Plon
Stacey L. Berg
Publication date: 01-07-2006
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2006
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-005-0135-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2006

5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice

CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors

Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme

Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment

Chemoprotection effect of retroviral vector encoding multidrug resistance 1 gene to allow intensified chemotherapy in vivo

Keynote webinar | Spotlight on antibody–drug conjugates in cancer